Bristol-Myers Squibb Co. will now be in the driver’s seat to monetize the assets gained from the myriad deals Celgene Corp. has forged. The pharma will need to mimic its history of using well-timed acquisitions...
Bridge Biotherapeutics Inc. (Seongnam, South Korea) and Daewoong Pharmaceutical Co. Ltd. (KSE:069620) partnered to co-develop BBT-401 to treat ulcerative colitis. Bridge will receive an undisclosed upfront payment and be eligible for up to $40 million...
Cancer metabolism is a prominent theme at this year’s ASH meeting, with researchers broadening the tent from metabolic targets that drive hematologic malignancies to those that intersect with other hot topics, notably immuno-oncology and epigenetics....
Researchers at the German Cancer Research Center have identified synthetic lethal markers beyond BRCA that expand the pool of patients who may benefit from PARP inhibitors and other compounds targeting DNA damage repair pathways. In...
Bridge Biotherapeutics Inc. (Seongnam, South Korea) said single and multiple ascending doses of oral ulcerative colitis candidate BBT-401 were well tolerated with minimal systemic exposure observed in a Phase I trial in 80 healthy volunteers....
Protein degradation company Kymera Therapeutics LLC (Cambridge, Mass.) closed an untranched $65 million series B round on Nov. 13 to bring its lead program into the clinic. Kymera is developing heterobifunctional molecules that bind to...
As the protein degradation space continues to gain traction, Kymera Therapeutics LLC has attracted interest from investors to the tune of $65 million to bring its first program to the clinic. 6 Dimensions Capital, Bessemer...
Protein degradation company Kymera Therapeutics LLC (Cambridge, Mass.) closed an untranched $65 million series B round to bring its lead program into the clinic. Kymera is developing heterobifunctional molecules that bind to both an E3...
With more than 60 partnerships under its belt, HitGen Ltd. has become a major gateway for companies to access DNA-encoded library technology -- a high efficiency form of combinatorial chemistry that upstages high throughput screening....
A Science study published Thursday suggests selective degradation of hard-to-drug zinc finger transcription factors could be achieved by modifying thalidomide or its analogs, collectively called imids. The results put forth a recipe to predict which...